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Introduction: 
 
Bariatric surgery is being increasingly investigated as treatment for Type II Diabetes Mellitus (T2DM). As 
Sleeve Gastrectomy (SG) surpasses Roux-en-Y Gastric Bypass (RYGB) as the new standard in bariatric 
surgery, it is still unknown if its efficacy in achieving remission is comparable to RYGB. This study compared 
diabetic remission rates between SG and RYGB in order to identify the predictive factors for remission and the 
mechanisms of achieving remission. 
 
Methods: 
 
This was a retrospective cohort study comparing all diabetic patients undergoing RYGB and SG at an 
academic medical center from 1/1/11-7/1/15. Patients were followed preoperatively and at 6 week, 6 month, 
and 1, 2, and 3 year intervals. We defined diabetic remission as HbA1c under 7 without insulin or 
hypoglycemic use and excess body weight (EBW) as percent over ideal body weight. Data were analyzed 
using Cox analysis, Fisher’s Exact Tests, and Student T Tests. 
 
Results: 
 
During the study, 96 patients underwent RYGB and 89 underwent SG. Preoperatively, patients from both 
groups had similar age, weight, gender, preoperative weight loss, HbA1c at onset and at surgery, oral 
hypoglycemic use, insulin use, and HOMA2 parameters. At one year postoperatively, patients who underwent 
RYGB showed a statistically greater postoperative EBW loss (62% vs. 36% p<0.0001). Kaplan Meier analysis 
showed a significantly higher rate of remission, (83% vs. 66%) in patients who underwent SG (p=0.02). After 
using Cox analysis to account for differences in delta BMI (p=0.04), EBW loss (p=0.04), preoperative HOMA2 
parameters (p=0.008-0.011), and preoperative factors such as HbA1c and insulin use (p=0.001 for both), there 
was no change in RYGB’s impact on diabetic remission compared to SG. 
 
Conclusion: 
 
Our results confirm that RYGB achieves a significantly greater rate of diabetic remission and a significantly 
higher weight loss than SG. Additionally, the difference in rate of diabetic remission is not explained by weight 
loss or preoperative predictors of less reversible diabetes (HOMA2 parameters, use of insulin). Identification of 
the factor(s) responsible for this differential effect on diabetes may afford opportunity for therapeutic 
intervention. 
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